ReviewCell death & disease2018
Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract.
Review in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Spleen volume in relation to ulcerative colitis and Crohn's disease: a Mendelian randomization study.Scientific reports · 2025Pooled it
- Debate on the relationship betweenFrontiers in microbiology · 2024Pooled it
- Helicobacter pylori promote M1 macrophage polarization via JAK3-mediated activation of the SOCS3/IL2RA axis to suppress host immunity.Archives of microbiology · 2026Article
- The Molecular Interplay Between Helicobacter pylori Infection and Ulcerative Colitis: Unraveling Shared Biomarkers and Pathway Networks.Immunity, inflammation and disease · 2026Article
- Polyp Tissue LRG1 Protein Levels andInternational journal of general medicine · 2026Article
- Effect ofTherapeutic advances in gastroenterology · 2026Review
- Relationship between Epstein-Barr virus and inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Lactiplantibacillus plantarum ZJ316 Alleviates Helicobacter pylori-Induced Intestinal Inflammation by Sustaining Intestinal Homeostasis.Probiotics and antimicrobial proteins · 2025Article
- Risk of primary sclerosing cholangitis among patients with gastritis: a nationwide cohort study.European journal of epidemiology · 2025Article
- The Controversies in the Relationship BetweenJournal of clinical medicine · 2025Review
- Prevalence of H. Pylori in inflammatory bowel disease patients and its association with severity.BMC gastroenterology · 2025Article
- Editorial: The role of bioactive compounds and nutrients in intestinal mucosal immunity, liver and vascular inflammation.Frontiers in immunology · 2025Article
- Role of gut microbiota andWorld journal of gastroenterology · 2024Review
- Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis.IBRO neuroscience reports · 2024Review
- Stimulus-responsive biomaterials for Helicobacter pylori eradication.Journal of advanced research · 2024Review
- Bibliometric analysis of the correlation between H. pylori and inflammatory bowel disease.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Molecular design of hydroxamic acid-based derivatives as urease inhibitors of Helicobacter pylori.Molecular diversity · 2024Article
- Experimental Inoculation ofInternational journal of molecular sciences · 2024Article
- Comparative Assessment of the Anti-Cells · 2024Article
- Dual RNA sequencing ofmSystems · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori has coexisted with humans for approximately 60,000 years and greater than 50% of the global population is infected with H. pylori. H. pylori was successfully cultured in vitro in 1983 and studies of H. pylori have achieved substantial advances over the last 35 years. Since then, H. pylori has been characterized as the primary pathogenic factor for chronic gastritis, peptic ulcer, and gastric malignancy. Numerous patients have received H. pylori eradication treatment, but only 1-2% of H. pylori-infected individuals ultimately develop gastric cancer. Recently, numerous epidemiological and basic experimental studies suggested a role for chronic H. pylori infection in protecting against inflammatory bowel disease (IBD) by inducing systematic immune tolerance and suppressing inflammatory responses. Here we summarize the current research progress on the association between H. pylori and IBD, and further describe the detailed molecular mechanism underlying H. pylori-induced dendritic cells (DCs) with the tolerogenic phenotype and immunosuppressive regulatory T cells (Tregs). Based on the potential protective role of H. pylori infection on IBD, we suggest that the interaction between H. pylori and the host is complicated, and H. pylori eradication treatment should be administered with caution, especially for children and young adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.